Literature DB >> 11817328

CD40:CD40L interactions in X-linked and non-X-linked hyper-IgM syndromes.

A Bhushan1, L R Covey.   

Abstract

Hyper-IgM (HIM) syndrome is a rare immunodeficiency characterized by low or absent IgG, IgA, and IgE with normal or elevated levels of IgM. This disorder can be acquired or familial with either X-linked or autosomal patterns of inheritance. The X-linked form of the disease is a consequence of mutations in the CD40 ligand (CD40L) gene that encodes a protein expressed primarily on activated CD4+ T cells. The cognate interaction between CD40L on T cells and CD40 on antigen-stimulated B cells, macrophage, and dendritic cells is critical for the development of a comprehensive immune response. The non-X-linked form of HIM syndrome is heterogeneous and appears in some cases to be a consequence of mutations in the AlD gene which encodes a B cell specific protein required for class switch recombination, somatic mutation, and germinal center formation. However, mutations in other unidentified genes are clearly the basis of the disease in a subset of patients. In this article, we review the essential features of the X-linked and non-X-linked forms of HIM syndrome and discuss the critical role the CD40:CD40L receptor-ligand pair plays in the pathogenesis of these immune deficiencies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11817328     DOI: 10.1385/IR:24:3:311

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  116 in total

1.  Clinical spectrum of X-linked hyper-IgM syndrome.

Authors:  J Levy; T Espanol-Boren; C Thomas; A Fischer; P Tovo; P Bordigoni; I Resnick; A Fasth; M Baer; L Gomez; E A Sanders; M D Tabone; D Plantaz; A Etzioni; V Monafo; M Abinun; L Hammarstrom; T Abrahamsen; A Jones; A Finn; T Klemola; E DeVries; O Sanal; M C Peitsch; L D Notarangelo
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  A novel RING finger protein interacts with the cytoplasmic domain of CD40.

Authors:  H M Hu; K O'Rourke; M S Boguski; V M Dixit
Journal:  J Biol Chem       Date:  1994-12-02       Impact factor: 5.157

3.  Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM.

Authors:  R Fuleihan; N Ramesh; R Loh; H Jabara; R S Rosen; T Chatila; S M Fu; I Stamenkovic; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

4.  Structure of germ line immunoglobulin alpha heavy-chain RNA and its location on polysomes.

Authors:  G Radcliffe; Y C Lin; M Julius; K B Marcu; J Stavnezer
Journal:  Mol Cell Biol       Date:  1990-01       Impact factor: 4.272

Review 5.  Immunoglobulin class switching.

Authors:  J Stavnezer
Journal:  Curr Opin Immunol       Date:  1996-04       Impact factor: 7.486

6.  Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection.

Authors:  L Soong; J C Xu; I S Grewal; P Kima; J Sun; B J Longley; N H Ruddle; D McMahon-Pratt; R A Flavell
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

7.  Immunologic studies of three family members with the immunodeficiency with hyper-IgM syndrome.

Authors:  Z Brahmi; K H Lazarus; M E Hodes; R L Baehner
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

Review 8.  Immune regulation by CD40 and its ligand GP39.

Authors:  T M Foy; A Aruffo; J Bajorath; J E Buhlmann; R J Noelle
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

9.  TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling.

Authors:  T K Ishida; T Tojo; T Aoki; N Kobayashi; T Ohishi; T Watanabe; T Yamamoto; J Inoue
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

10.  Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2).

Authors:  P Revy; T Muto; Y Levy; F Geissmann; A Plebani; O Sanal; N Catalan; M Forveille; R Dufourcq-Labelouse; A Gennery; I Tezcan; F Ersoy; H Kayserili; A G Ugazio; N Brousse; M Muramatsu; L D Notarangelo; K Kinoshita; T Honjo; A Fischer; A Durandy
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

View more
  12 in total

1.  Deregulated expression of CD40 ligand in HTLV-I infection: distinct mechanisms of downregulation in HTLV-I-transformed cell lines and ATL patients.

Authors:  Nicole S Harhaj; Branislava Janic; Juan C Ramos; William J Harrington; Edward W Harhaj
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

Review 2.  The role of platelet CD154 in the modulation in adaptive immunity.

Authors:  Daniel L Sprague; Jennifer M Sowa; Bennett D Elzey; Timothy L Ratliff
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

3.  Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.

Authors:  Rhea N Coler; Thomas Hudson; Sean Hughes; Po-Wei D Huang; Elyse A Beebe; Mark T Orr
Journal:  J Immunol       Date:  2015-08-21       Impact factor: 5.422

4.  Aging murine B cells have decreased class switch induced by anti-CD40 or BAFF.

Authors:  Daniela Frasca; Richard L Riley; Bonnie B Blomberg
Journal:  Exp Gerontol       Date:  2006-10-25       Impact factor: 4.032

5.  Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.

Authors:  Erminia Ridolo; Francesco Pucciarini; Maria Cristina Nizi; Eleni Makri; Paola Kihlgren; Lorenzo Panella; Cristoforo Incorvaia
Journal:  Hum Vaccin Immunother       Date:  2020-05-13       Impact factor: 3.452

6.  CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome.

Authors:  Xiying Fan; Bhaskar Upadhyaya; Liming Wu; Christopher Koh; Mónica Santín-Durán; Stefania Pittaluga; Gulbu Uzel; David Kleiner; Ester Williams; Chi A Ma; Aaron Bodansky; Joao B Oliveira; Pamela Edmonds; Ronald Hornung; Duane W Wong; Ronald Fayer; Tom Fleisher; Theo Heller; Calman Prussin; Ashish Jain
Journal:  Clin Immunol       Date:  2012-02-07       Impact factor: 3.969

7.  Partial immune reconstitution of X-linked hyper IgM syndrome with recombinant CD40 ligand.

Authors:  Ashish Jain; Joseph A Kovacs; David L Nelson; Stephen A Migueles; Stefania Pittaluga; William Fanslow; Xiying Fan; Duane W Wong; Justin Massey; Ronald Hornung; Margaret R Brown; Jacob J Spinner; Shuying Liu; Victoria Davey; Harry A Hill; Hans Ochs; Thomas A Fleisher
Journal:  Blood       Date:  2011-08-12       Impact factor: 22.113

Review 8.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

9.  TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-κB1 Activation.

Authors:  Rachel A Woolaver; Xiaoguang Wang; Yonatan Dollin; Ping Xie; Jing H Wang; Zhangguo Chen
Journal:  J Immunol       Date:  2018-10-19       Impact factor: 5.422

Review 10.  Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency.

Authors:  Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robyn E O'Hehir; Menno C van Zelm
Journal:  Cell Mol Immunol       Date:  2020-08-17       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.